Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Nawwar Al-Attar
Dilatation of the ascending aorta beyond the critical limit of 50 mm is associated with a significant risk of aortic dissection or rupture in the absence of surgical treatment. Depending on the localisation of the aneurismal dilatation, surgical correction by replacement with a Dacron tube may be extended to include reimplantation of the coronary ostia and a valvular procedure.
Aortic aneurysms carry a risk of acute aortic dissection or rupture in the absence of surgical treatment. Indeed aortic dissections or ruptures are the 13th cause of death in Western countries (1, 2). Their incidence is estimated at around 4.5 per 100 000 persons. Aneurysms of the ascending aorta make up for more than half of all thoracic aneurysms (1-3), with men being affected more than women. Aortic aneurysms carry a risk of acute aortic dissection or rupture in the absence of surgical treatment. Indeed aortic dissections or ruptures are the 13th cause of death in Western countries (1, 2). Their incidence is estimated at around 4.5 per 100 000 persons. Aneurysms of the ascending aorta make up for more than half of all thoracic aneurysms (1-3), with men being affected more than women.
Aortic aneurysms carry a risk of acute aortic dissection or rupture in the absence of surgical treatment. Indeed aortic dissections or ruptures are the 13th cause of death in Western countries (1, 2). Their incidence is estimated at around 4.5 per 100 000 persons. Aneurysms of the ascending aorta make up for more than half of all thoracic aneurysms (1-3), with men being affected more than women.
Aortic aneurysms can be classified to 2 distinct types:
1. Aortic root aneurysms (figure 1): the dilatation of the aorta involves the initial portion of the aorta and includes the sinuses of Valsalva. They may be associated with connective tissue disorders (e.g. Marfan’s Syndrome) and patients are usually young (30-50 yrs).Their management often includes replacement or repair of the aortic valve.
2. Supravalvular aortic aneurysms (figure 2): these involve the ascending thoracic aorta above the sinuses of Valsalva. The main aetiological process is atherosclerotic disease thus patients are usually older (55-70 yrs). Their treatment does not necessarily incorporate a valvular procedure (2).
The average annual growth of ascending aortic aneurysms is 1–4 mm. However, this rate is greater in patients with Marfan’s syndrome or with bicuspid valves. Larger aneurysms also grow at a faster rate. Other factors that contribute to accelerated dilatation are smoking, high blood pressure, renal failure, male sex, fibrocalcific changes in the aortic valve, and left ventricular wall motion abnormalities (2). When the aorta reaches 6 cm in size, reported yearly rates of rupture, dissection, and death are 3.6%, 3.7%, and 10.8%, respectively (4).
Most aneurysms have a long latent period before clinical symptoms appear. Diagnosis is thus established incidentally in many cases during an imaging examination on the chest (chest XR, echocardiography…etc.). Symptoms from compression of adjacent structures can be the presenting feature: chronic chest pain, cough, dysphagia can result from pressure on the sternum, trachea or oesophagus respectively. However in 75% of patients, the first presentation is with acute sudden severe tearing chest pain. This is highly suggestive of imminent rupture or aortic dissection and requests urgent medical care.
Diagnosis is confirmed by echocardiography which also evaluates valvular competency. CT scan with injection of contrast material together with 3D reconstruction permits accurate measurement of the aortic diameters and to establish reference values for follow up (figure 3). MRI offers similar diagnostic facilities. Aortography is only performed if a surgical intervention is being planned and should incorporate coronary artery angiography as part of preoperative work up.
ß-blockers are indicated in asymptomatic patients during the follow up period for patients not requiring surgery. Their negative inotropic and chronotropic effects decrease the rate and rise of the arterial pulse with a delay in aortic root dilatation and have been shown to improve survival particularly in patients with Marfan’s syndrome (5,6). Since aortic aneurysms can be hereditary, a detailed family history and evaluation of other family members should be carried out.
Surgical intervention is performed under cardiopulmonary bypass through median sternotomy. The overall indications for surgery are cited in table 1. Immediate and emergency surgery is indicated in patients with acute rupture or dissection of the aortic aneurysm and evidently, is associated with considerable morbi-mortality (30 % vs. 4.3% in emergency versus elective surgery, respectively) (7). These high figures of morbi-mortality associated with emergency surgery highlight the importance of prior diagnosis and meticulous follow up.
The decision to perform elective surgery is directly related to the progression of the aortic diameter and the aetiology of the aneurysm (6,8). Table 2 summarises the current French, American and European guidelines for the indication of surgery in aneurysms of the ascending thoracic aorta.
Supravalvular aneurysms can be treated by a simple supracoronary tube graft (figure 4), whereas aortic root aneurysms need a Bentall (incorporating an aortic valve replacement) or valve sparing procedure with reimplantation of the coronary ostia which are found within the diseased zone.
The choice of the surgical technique depends on the type of the aneurysm, aetiology, patient life expectancy and the presence of contraindications to anticoagulation. Table 1. Indications for surgery
1. Aneurysms with greatest diameter > 55 mm measured by CT scan with injection of contrast material or MRI.
2. Symptomatic aortic regurgitation.
3. History of systemic embolism from a mural thrombus.
4. Symptoms from compression of adjacent structures.
5. Rupture or acute aortic dissection.
Table 2 :Current French, American and European guidelines for the indication of surgery in aneurysms of the ascending thoracic aorta
Figure 1. Aortic root aneurysm
Figure 2. Supralvular aortic aneurysm Figure 3. CT scan with injection of contrast material and 3D reconstruction
Figure 4: Surgical replacement of the ascending aorta by Dacron tube. (LV: left ventricle, RA : right atrium) The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1 Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982;92:1103–8.
2 Coady MA, Rizzo JA, Goldstein LJ, et al. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999;17:615–35.
3 Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005;111:816–28.
4. Nataf P, Lansac E. Dilation of the thoracic aorta: medical and surgical management. Heart 2006;92;1345-1352
5. Jondeau G, Barthelet M, Baumann C, et al. Recommandations sur la prise en charge médicamenteuse des atteintes aortiques du syndrome de Marfan. Arch Mal Cœur Vaiss 2006 May;99:540-6.
6. Iung B, Gohlke-Barwolf C, Tornos P, et al for the Working Group on Valvular Heart Disease. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 2002;23:1252–66.
7. Eagle KA, Burkmann D, Isselbacher E, et al: Predictive of mortality in patients with type A acute aortic dissections: results from the International Registry of Acute Aortic Dissection (IRAD). J Am Coll Cardiol 2000; 35:223.
8 Bonow RO, Carabello B, de Leon AC, et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol 1998;32:1486–8.
9. Recommandations de la Société française de cardiologie concernant la prise en charge des valvulopathies acquises et des dysfonctions de prothèse valvulaire - indications opératoires et interventionnelles  ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, tome 98, n° 2 (suppl), février 2005)
10. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation. 2006 1;114(5):e84-231. 11. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230-68.
Pr N. Al-Attar Paris, France Web editor for the working group on cardiovascular surgery
© 2017 European Society of Cardiology. All rights reserved